Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 16 de 16
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
2.
Eur J Clin Pharmacol ; 31(4): 463-8, 1986.
Artigo em Inglês | MEDLINE | ID: mdl-3643850

RESUMO

The pharmacokinetics of naproxen have been examined in 13 elderly patients (mean age 84.2 years) and in 9 younger patients (mean age 53.9 years) at the end of a 21 day course of therapy with naproxen 500 mg b.d. The mean pre-dose concentration on days 19, 20 and 21 was significantly higher in the elderly patients than in the controls (60.1 vs. 43.3 micrograms X ml-1). The AUC (0-24) was significantly higher in the elderly subjects only when normalized for body weight (9.1 vs. 5.4 micrograms X ml-1 X h kg-1 p less than or equal to 0.02). The AUC was significantly higher in the elderly group compared to the control group also in the normalized form. The apparent clearance of naproxen was reduced in the elderly compared to the control patients (315 vs. 628 ml X h-1). The percentage protein binding of naproxen was the same in both groups (99.8%) but the free concentration of naproxen was significantly higher in the elderly patients than in the control patients (141 vs. 89.8 ng X ml-1). Although there was no excess of side effects in the elderly patients it is suggested that when naproxen is given to elderly patients, therapy should be started at the lower end of the dosage range.


Assuntos
Envelhecimento/sangue , Naproxeno/sangue , Osteoartrite/sangue , Adulto , Idoso , Idoso de 80 Anos ou mais , Proteínas Sanguíneas/metabolismo , Feminino , Meia-Vida , Humanos , Cinética , Masculino , Pessoa de Meia-Idade , Naproxeno/uso terapêutico , Osteoartrite/tratamento farmacológico , Ureia/sangue
4.
Br J Clin Pharmacol ; 14(2): 286-9, 1982 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-7104182

RESUMO

Fifteen patients with rheumatoid arthritis received indomethacin in three treatment schedules; indomethacin retard 75 mg twice daily; indomethacin capsules 50 mg three times daily; and indomethacin 100 mg suppository at night with 50 mg by mouth each morning. The study was a double-blind, double-dummy one with each treatment being given for 2 weeks after a washout period of 3 days. After the washout period, and at the end of each 2 week active treatment period, blood samples were taken during a dosage interval for assay of indomethacin concentrations in plasma. Clinical assessments were also performed. All three treatment period produced significant clinical improvements in the assessments compared with the placebo washout period. However, no differences were seen between the treatments. Side effects occurred with equal frequency in all three periods, and the anticipated reduction in central nervous system side effects during the indomethacin retard period was not seen. Plasma concentrations of indomethacin were significantly higher during indomethacin retard therapy with a peak concentration of 2500 +/- 25 ng ml-1 during indomethacin retard therapy (mean +/- s.d.) and 1900 +/- 200 ng ml during conventional oral therapy. Indomethacin retard is as effective as the other formulations of indomethacin but appears to offer no significant advantages.


Assuntos
Indometacina/administração & dosagem , Idoso , Artrite Reumatoide/tratamento farmacológico , Preparações de Ação Retardada , Feminino , Humanos , Indometacina/metabolismo , Cinética , Masculino , Pessoa de Meia-Idade
5.
Rheumatol Rehabil ; 21(2): 65-71, 1982 May.
Artigo em Inglês | MEDLINE | ID: mdl-7079658

RESUMO

Delineation of lymphatic vessels is a frequent finding in arthrograms of rheumatoid joints. Arthrography of the rheumatoid wrist when associated with oedema of the upper limb reveals a characteristic pattern consistent with lymphatic obstruction. In our opinion, these findings may be regarded as further evidence in favour of lymphatic obstruction as the cause of peripheral oedema in rheumatoid arthritis. The syndrome appears to be a separate entity from idiopathic oedema of women.


Assuntos
Artrite Reumatoide/diagnóstico por imagem , Linfedema/etiologia , Punho/diagnóstico por imagem , Adulto , Idoso , Artrite Reumatoide/complicações , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Radiografia
8.
Br J Clin Pharmacol ; 10(4): 387-92, 1980 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-7004474

RESUMO

1 Indomethacin 100 mg nightly for 1 week has been administered to 13 patients with rheumatoid arthritis by both oral and rectal routes in a double-blind, randomized, cross-over study. 2 Clinical assessments were performed at 09.00 and 14.00 h on the last 3 days of each active treatment period and compared to the results on the last 2 days of the placebo control period. 3 Indomethacin produced significant improvements in the clinical assessments at both 09.00 and 14.00 h compared to placebo but not differences were seen between the two routes of administration. 4 No significant difference was seen in the side effects experienced in the two periods. 5 The mean (+/- s.e. mean) plasma indomethacin concentration at 09.00 h in the oral period was 200.3 +/- 27.4 ng/ml, not significantly different from that in the suppository period (220.0 +/- 28.9 ng/ml). 6 Indomethacin 100 mg nightly by mouth is as effective as a 100 mg suppository and easier to administer.


Assuntos
Artrite Reumatoide/tratamento farmacológico , Indometacina/administração & dosagem , Administração Oral , Ensaios Clínicos como Assunto , Método Duplo-Cego , Feminino , Humanos , Indometacina/efeitos adversos , Indometacina/sangue , Indometacina/uso terapêutico , Masculino , Pessoa de Meia-Idade , Supositórios
9.
Scand J Rheumatol ; 9(1): 52-4, 1980.
Artigo em Inglês | MEDLINE | ID: mdl-7375871

RESUMO

Twenty-one patients with rheumatoid arthritis were given indomethacin 25 mg t.i.d. by mouth for 3 weeks followed by indomethacin 25 mg t.i.d. plus a 100 mg suppository at night, after a 5-day period on placebo capsules. The mean (+/- S.E.) 24-hour creatinine clearance was 57.8 +/- 5.7 ml/min in the placebo period and was not significantly altered during indomethacin therapy, 53.1 +/- 5.5 ml/min in the oral period and 56.6 +/- 6.4 ml/min in the oral plus suppository period (P greater than 0.1). In 6 volunteers, duplicate 2-hour creatinine clearances were performed after a single oral dose of 50 mg indomethacin. After placebo capsules the mean creatinine clearance was 133.7 +/- 9.5 ml/min and after 50 mg indomethacin it was 126.5 +/- 8.9 ml/min (P greater than 0.1). In 4 of the volunteers the mean creatinine clearance after 8 days on indomethacin 25 mg q.i.d. was 117.1+/- 5.3 ml/min (P greater than 0.1). Indomethacin plasma concentrations were in the usual range for the dose given. Indomethacin caused no reduction in the creatinine clearance in spite of causing significant inhibition of prostaglandin E synthesis.


Assuntos
Indometacina/efeitos adversos , Rim/efeitos dos fármacos , Administração Oral , Adolescente , Adulto , Idoso , Creatinina/sangue , Creatinina/urina , Feminino , Taxa de Filtração Glomerular/efeitos dos fármacos , Humanos , Indometacina/administração & dosagem , Masculino , Pessoa de Meia-Idade , Placebos , Supositórios , Fatores de Tempo
12.
Ann Rheum Dis ; 38(2): 128-36, 1979 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-375848

RESUMO

Twenty patients with definite or classical rheumatoid arthritis entered and completed a sequential study of placebo for 1 week, oral indomethacin 25 mg 3 times a day for 3 weeks, and oral indomethacin 25 mg 3 times a day plus 100 mg indomethacin suppository at night for 3 weeks. Twelve of the patients had previously been classified as responders and eight as nonresponders to indomethacin by an independent assessor. At the end of each period patients were assessed by a blind observer for duration of morning stiffness, pain score, digital joint size, grip strength, articular index, analgesic tablet usage, and the patient's own overall global assessment and comparative global assessment. In 8 of the 9 tests used responders improved on indomethacin in comparison with placebo, while nonresponders did not improve. There were no significant differences between responders and nonresponders in the plasma half-life, plasma clearance of indomethacin, protein binding of indomethacin, or urinary excretion of free or conjugated indomethacin. There were no significant differences between responders and nonresponders in the urinary excretion of 7HDPA or in the platelet aggregation or platelet malonyldialdehyde production tests. In responders there was a significant positive correlation between the plasma indomethacin concentration (r=0.44, P<0.05) and the percentage inhibition of malonyldialdehyde production by the platelets. However, in nonresponders this correlation, while significant (P<0.05), was negative (r=-0.498). Both for responders and nonresponders there was a significant correlation between plasma indomethacin concentration and the percentage reduction in 7HDPA. There was no correlation between the clinical response and the plasma concentration of indomethacin. There appears to be a biochemical difference between responders and nonresponders, which, while not necessarily causally linked with the clinical response to indomethacin, is worthy of further study.


Assuntos
Artrite Reumatoide/tratamento farmacológico , Indometacina/uso terapêutico , Adulto , Idoso , Artrite Reumatoide/sangue , Artrite Reumatoide/urina , Plaquetas/efeitos dos fármacos , Ensaios Clínicos como Assunto , Feminino , Humanos , Indometacina/sangue , Indometacina/urina , Masculino , Pessoa de Meia-Idade , Agregação Plaquetária/efeitos dos fármacos
13.
Clin Pharmacol Ther ; 24(3): 298-307, 1978 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-688724

RESUMO

The interaction between indomethacin and probenecid has been studied in 17 patients with rheumatoid arthritis with the use of a specific gas-liquid chromatographic method for the assay of indomethacin in plasma and urine. Probenecid in a dose of 0.5 gm twice daily improved the therapeutic response to indomethacin administered in a dose of 25 mg 3 times daily for a 3-wk period. There was an increase in the mean AUC of indomethacin in plasma from 2,553 +/- 213 hr ng/ml to 4,181 +/- 384 hr ng/ml when probenecid was given, but there was no change in the plasma half-life of indomethacin. There was a reduction in the mean plasma clearance of indomethacin from 174 +/- 21 ml/kg/hr to 107 +/- 14 ml/kg/hr when probenecid was added to the indomethacin therapy and a decrease in the apparent volume of distribution from 0,927 +/- 0.16 L/kg to 0.613 +/- 0.13 L/kg. There was no change in the amount of free indomethacin excreted in the urine during probenecid therapy but there was a reduction in the urinary excretion of free plus glucuronide conjugate of indomethacin from 8,967 +/- 867 microgram/day to 4,760 +/- 674 microgram/day, with a fall in the mean renal clearance of indomethacin glucuronide from 271 +/- 48 ml/min to 126 +/- 57.0 ml/min. The changes in the plasma indomethacin concentration profile during probenecid therapy are due to a decrease in the nonrenal clearance of indomethacin possibly because of reduced biliary clearance.


Assuntos
Indometacina/metabolismo , Probenecid/metabolismo , Adulto , Artrite Reumatoide/tratamento farmacológico , Artrite Reumatoide/metabolismo , Proteínas Sanguíneas/metabolismo , Interações Medicamentosas , Quimioterapia Combinada , Feminino , Meia-Vida , Humanos , Indometacina/uso terapêutico , Cinética , Masculino , Pessoa de Meia-Idade , Probenecid/uso terapêutico , Ligação Proteica
14.
Ann Rheum Dis ; 34(5): 409-15, 1975 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-769706

RESUMO

Investigation of 44 paired test and control patients, all suffering from rheumatoid arthritis, following exposure to phenylbutazone (PBZ) and/or oxyphenbutazone (OPB), suggests that there is no significant increase in the level of chromosomal damage in lymphocytes. The control subjects comprised two series, one previously exposed to PBZ and/or OPB, but not for at least 1-5 years, and the other never exposed to PBZ or OPB. No significant difference in the level of chromosome damage was found between patients never exposed, previously exposed, or now receiving PBZ and/or OPB.


Assuntos
Cromossomos/efeitos dos fármacos , Fenilbutazona/farmacologia , Ensaios Clínicos como Assunto , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Oxifenilbutazona/farmacologia , Fenilbutazona/sangue , Classe Social , Fatores de Tempo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...